Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 14/20 | 0.83 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.81 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.81 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.62 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL11563217 | 0.99 | OPRM1 (0.81) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL11563515 | 0.93 | OPRM1 (0.78) | OPRM1OPRD1OPRK1CACNA1C | |
| Carfentanil SCHEMBL9737212 | 0.92 | OPRM1 (0.96) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| Hydrochloric Acid SCHEMBL11565270 | 0.91 | OPRM1 (0.81) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL11566707 | 0.91 | OPRM1 (0.85) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| [11C]-Carfentanil SCHEMBL29374424 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| Oxalic Acid SCHEMBL6045761 | 0.89 | OPRM1 (0.67) | OPRM1OPRD1OPRK1CACNA1C | |
| SCHEMBL11565333 | 0.89 | OPRM1 (0.73) | OPRM1OPRD1OPRK1 | |
| Carfentanil SCHEMBL116222 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| Hydrochloric Acid SCHEMBL11564521 | 0.89 | OPRM1 (0.72) | OPRM1OPRD1OPRK1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1559428-A1 | RECEPTOR REGULATOR | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | NMUR1, NMUR2, NMBR | OPRM1 148/4885OPRD1 180/4885OPRK1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.